Association of Adjuvant Chemotherapy in Patients With Resected Pancreatic Adenocarcinoma After Multiagent Neoadjuvant Chemotherapy

医学 内科学 危险系数 比例危险模型 胰腺癌 化疗 病态的 回顾性队列研究 肿瘤科 队列 腺癌 阶段(地层学) 新辅助治疗 癌症 外科 乳腺癌 置信区间 古生物学 生物
作者
Toshitaka Sugawara,Salvador Rodriguez Franco,Samantha Sherman,Michael J. Kirsch,Kathryn L. Colborn,Jun Ishida,Samuele Grandi,Mohammed H. Al-Musawi,Ana Gleisner,Richard David Schulick,Marco Del Chiaro
出处
期刊:JAMA Oncology [American Medical Association]
卷期号:9 (3): 316-316 被引量:51
标识
DOI:10.1001/jamaoncol.2022.5808
摘要

Importance: The total number of patients with pancreatic ductal adenocarcinoma (PDAC) who receive neoadjuvant chemotherapy (NAC) is increasing. However, the added role of adjuvant chemotherapy (AC) in these patients remains unknown. Objective: To evaluate the association of AC with overall survival (OS) in patients with PDAC who received multiagent NAC followed by curative-intent surgery. Design, Setting, and Participants: This retrospective, matched-cohort study used data from the National Cancer Database and included patients with PDAC diagnosed between 2010 and 2018. The study included patients at least 18 years of age who received multiagent NAC followed by surgical resection and had available records of the pathological findings. Patients were excluded if they had clinical or pathological stage IV disease or died within 90 days of their operation. Exposures: All included patients received NAC and underwent resection for primary PDAC. Some patients received adjuvant chemotherapy. Main Outcomes and Measures: The main outcome was the OS of patients who received AC (AC group) vs those who did not (non-AC group). Interactions between pathological findings and AC were investigated in separate multivariable Cox regression models. Results: In total, 1132 patients (mean [SD] age, 63.5 [9.4] years; 577 [50.1%] male; 970 [85.7%] White) were included, 640 patients in the non-AC group and 492 patients in the AC group. After being matched by propensity score according to demographic and pathological characteristics, 444 patients remained in each group. The multivariable Cox regression model adjusted for all covariates revealed an association between AC and improved survival (hazard ratio, 0.71; 95% CI, 0.59-0.85; P < .001). Subgroup interaction analysis revealed that AC was significantly associated with better OS (26.6 vs 21.2 months; P = .002), but the benefit varied by age, pathological T category, and tumor differentiation. Of note, AC was associated with better survival in patients with any pathological N category and positive margin status. Conclusions and Relevance: In this cohort study, AC following multiagent NAC and resection in patients with PDAC was associated with significant survival benefit compared with that in patients who did not receive AC. These findings suggest that patients with aggressive tumors may benefit from AC to achieve prolonged survival, even after multiagent NAC and curative-intent resection.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
冯小晴完成签到 ,获得积分10
刚刚
刚刚
刚刚
刚刚
June完成签到,获得积分10
刚刚
1秒前
困告完成签到,获得积分10
1秒前
1秒前
1秒前
飞天小李警完成签到,获得积分10
1秒前
1秒前
穆梦山完成签到,获得积分10
2秒前
Clover04的应助被籽儿采纳,获得10
2秒前
kki完成签到 ,获得积分10
2秒前
水煮电吹风的应助被卓卓卓采纳,获得10
2秒前
Akim的应助被请较老嘚采纳,获得10
2秒前
3秒前
4秒前
4秒前
4秒前
lllliiii发布了新的文献求助10
4秒前
Azumah发布了新的文献求助10
5秒前
困告发布了新的文献求助20
5秒前
5秒前
深情安青的应助被wyh2025采纳,获得10
5秒前
June发布了新的文献求助10
5秒前
方元浡发布了新的文献求助10
5秒前
6秒前
刘宇翔发布了新的文献求助30
6秒前
LV发布了新的文献求助10
7秒前
panpan完成签到,获得积分10
7秒前
蔡蔡小星完成签到,获得积分10
7秒前
害羞的灯泡完成签到,获得积分20
7秒前
yzm完成签到,获得积分10
7秒前
8秒前
9秒前
xx发布了新的文献求助10
9秒前
生动寒凝完成签到,获得积分10
9秒前
9秒前
希望天下0贩的0的应助被LV采纳,获得10
10秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
Social Psychology in the Real World 600
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8181072
求助须知:如何正确求助?哪些是违规求助? 9571092
关于积分的说明 21816478
捐赠科研通 7777477
什么是DOI,文献DOI怎么找? 3433418
关于科研通互助平台的介绍 2557638
邀请新用户注册赠送积分活动 2479460